Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Caroline Germa, MD
Ikena Oncology
Study Chair - Katherine Kim, MD
Ikena Oncology
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Peninsula South Eastern Haematology and Oncology Group (paso Medical)
Frankston, Victoria, Australia
- University Hospitals of Leicester Nhs Trust
Leicester, England, United Kingdom
- the Royal Marsden Hospital
London, England, United Kingdom
- the University of Chicago
Chicago, Illinois, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Start Midwest
Grand Rapids, Michigan, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
- University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania, United States
- Sarah Cannon Research Institute
Nashville, Tennessee, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- Next Oncology
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 7 Jan 2022
- Primary completion
- 27 Aug 2024
- Completion
- 9 Sept 2024
- Last update posted
- 18 Nov 2024
- Registered enrollment
- 67
- Registry id
- NCT05228015
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.